Atualizaçäo no uso das heparinas de baixo peso molecular 1999

Oliveira, Luiz Claudio Lazzarini de; Lacerda, Ana Paula Machado de.
Pulmäo RJ ; 8(1): 25-34, jan.-mar. 1999. tab
Artículo en Portugués | LILACS | ID: lil-248247

Documentos relacionados

  1. Low-Molecular-Weight Heparin Is Superior to Aspirin in the Prevention of Thromboembolic Disease: Or Is It?
  2. Low-Molecular-Weight Heparin Is Superior to Aspirin in the Prevention of Thromboembolic Disease: Or Is It?
  3. Analysis of the guidance and predictive value of uterine artery flow parameters in patients with recurrent spontaneous abortion.
  4. Antithrombotic therapy and digestive endoscopy.
  5. Combination anticoagulation strategy in pregnancy with mechanical valves: The KYBELE study.
  6. Heparin Bridging Therapy for Patients on Chronic Oral Anticoagulants in Periprocedural Settings.
  7. Anti-Xa level monitoring of low-molecular-weight heparin during intermittent venovenous hemofiltration.
  8. Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients.
  9. Comparison of the efficacy of low-molecular-weight heparin and fondaparinux sodium after total knee arthroplasty: a retrospective cohort study.
  10. [Evaluation of anticoagulant effect and predicted dose of low molecular weight heparin in hemodialysis by anti-Ⅹa factor activity].